Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07367971 · ClinicalTrials.gov registry record · Phase 1
Drug-Drug Interaction Study of ABP-671 in Gout Patients
A Phase 1 study, sponsored by Atom Therapeutics Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT07367971: Recruiting Phase 1 study, sponsored by Atom Therapeutics Co..
NCT07367971 is a Phase 1 study that is actively recruiting participants, run by Atom Therapeutics Co.. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07367971, a Phase 1 study, is actively recruiting participants, sponsored by Atom Therapeutics Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients. Pharmacokinetic (PK) interaction between ABP-671 and Allopurinol will be evaluated in participants who are on stable Allopurinol therapy.
Primary Outcome
Maximum observed plasma concentration (Cmax) of allopurinol following administration of allopurinol alone and in combination with ABP-671 at steady state.
Interventions
- DRUG ABP-671 plus allopurinol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-01-23 |
| Est. Completion | 2026-08-31 |
| Phase | Phase 1 |
What NCT07367971 shows while recruiting
NCT07367971 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 1 intervention - of which ABP-671 plus allopurinol is the first listed.
NCT07367971 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07367971 about?
NCT07367971 is a clinical study titled "Drug-Drug Interaction Study of ABP-671 in Gout Patients". This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients. Pharmacokinetic (PK) interaction between ABP-671 and Allopurinol will be evaluated in participants who are on stable Allopurinol therapy.
What is the current status of trial NCT07367971?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2026-01-23. Estimated completion is 2026-08-31.
What interventions are being tested in trial NCT07367971?
The interventions under investigation include: ABP-671 plus allopurinol (DRUG).
Who is sponsoring clinical trial NCT07367971?
This trial is sponsored by Atom Therapeutics Co., which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07367971's enrollment target sits among peer trials
20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI